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Abstract.
Background: Progressive external ophthalmoplegia (PEO) is an eye movement disorder characterised by paresis of the extra
ocular muscles and muscle restricted multiple mitochondrial DNA (mtDNA) deletions. Classification of patients is particularly
difficult due to overlapping phenotypes and a poor genotype-phenotype relationship. Despite the identification of several nuclear
encoded genes causing PEO, over half of patients with clinically confirmed PEO do not have a genetic diagnosis.
Objective: To systematically review genotypic and phenotypic correlates of published cases of adult-onset PEO.
Methods: Patients were identified from interrogation of articles from Scopus, Medline via PubMed, and Genetic Abstracts
databases using electronic searches (1st January 1970 to 8th November 2013). Reference lists and UniProt entries were also
manually checked for additional articles.
Results: Twelve nuclear encoded genes were identified (TYMP, SLC25A4, POLG, C10ORF2, OPA1, POLG2, RRM2B, TK2,
DGUOK, MPV17, MGME1, and DNA2) systematically from 583 patients. At the time of writing, mutations in SPG7 and AFG3L2
genes were reported to be associated with ophthalmoparesis and multiple mtDNA deletions in fourteen additional adult-onset
PEO patients, bringing the total number of known genes to fourteen.
Conclusions:Diagnostic yield is still critically dependent on the meticulous clinical and biochemical characterisation of patients.
Understanding the intimate relationship between genotype and phenotype remains a fundamental challenge. The results of this
systematic review provide guidance to both patients and clinician about future prognosis, and will serve, in future, to assess
methods of disease prevention and evaluation of targeted therapeutic strategies.
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INTRODUCTION
Progressive external ophthalmoplegia (PEO) is a
disorder biochemically delineated by skeletal mus-
cle restricted multiple mtDNA deletions [1]. PEO can
occur from single-point mutation or large-scale dele-
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tions of the mitochondrial (mt) DNA [2]. Defects of
several nuclear encoded genes encoding mitochondrial
proteins are also known to cause mtDNA instabil-
ity leading to PEO, including POLG, encoding the
only known mitochondrial DNA polymerase [3], twin-
kle protein encoded by C10ORF2 [4], and protein
p53R2 encoded by RRM2B [5]. Clinically, PEO is
characterised by progressive paralysis of the extra ocu-
lar muscles (Fig. 1). Ptosis (drooping of the eyelids)
and proximal myopathies are particularly common in
PEO patients. However, additional symptoms can also
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Fig. 1. The clinical, histochemical and mtDNA abnormalities associated with adult-onset Mendelian PEO and mitochondrial disease. A, Typical
clinical features of a patient with mitochondrial PEO; extraocular motility in cardinal directions of gaze is reduced with unusually marked restric-
tion of downgaze as the patient is asked to look left (i), right (ii), up, (iii) and down (iv). B, Sequential COX-SDH histochemisty of representative
diagnostic muscle biopsies showing the presence of scattered COX-deficient fibres in patients with various disorders of adult-onset mtDNA
maintenance abnormalities including (i) recessive (homozygous p.(Ala467Thr)) POLG mutations; (ii) a dominant, heterozygous p.(Gln458His)
C10ORF2 mutation; (iii) recessive (p.(Arg186Gly) and p.(Thr218Ile)) RRM2B mutations; (iv) recessive (p.(Asn288∗) and p.(Lys558∗)) SPG7
mutations; (C) Southern blotting of muscle DNA showing a control (lane 1), a single, large-scale mtDNA deletion (lane 2) and the typical
banding pattern observed with multiple mtDNA deletions (lanes 3 and 4); (D) Long-range PCR also indicating the presence of multiple mtDNA
deletions (lane 3) alongside a control (lane 2) and size markers (lane 1).
occur that include ataxia, psychiatric symptoms, sen-
sory axonal neuropathies, and optic atrophy.
The manifestation of PEO resulting from a nuclear
defect can be classified by the manner of inheritance,
into autosomal dominant PEO (adPEO) and autoso-
mal recessive PEO (arPEO). AdPEO is genetically
and clinically heterogeneous with mutations of several
nuclear encoded causative genes currently identified
including POLG [3], C10ORF2 [4], and SLC25A4 [6].
In comparison, arPEO is not as well defined and tends
to result in an early-onset presentation. In adult-PEO
patients, recessive mutations of POLG [3], TYMP [7],
TK2 [8], C10ORF2 [9], RRM2B [10], and DGUOK
[11] have been described.
PEO is poorly characterised due to indigent
genotype-phenotype correlates. Certain PEO patients
may present similar phenotypes, but may show diverse
genetic variation. Conversely, other patients may
present vastly differing phenotypes, but show little
genetic variation, often sharing mutations of the same
gene. Furthermore, despite the identification of sev-
eral nuclear encoded genes whereby mutations cause
PEO; a genetic diagnosis remains to be made in a siz-
able number of patients with clinically confirmed PEO
and a suspected nuclear defect.
To better understand the genotypic and phenotypic
heterogeneity of adult-onset PEO with mtDNA insta-
bility, we reviewed all reported patients in the literature
with adult-onset PEO.
METHODS
Selection Criteria and Search Strategy
The following inclusion criteria were determined:
• Adult patients (16 years or older) with PEO
defined as paralysis or restricted movement of
the extra ocular muscles and included patients
described with ‘ophthalmoplegia’, ‘ophthalmo-
paresis’, or paralysis of the extra ocular muscles
with or without additional clinical features;
• Exhibit biochemical evidence of mtDNA insta-
bility, either multiple mtDNA deletions, mtDNA
depletion, or both;
• Have a confirmed genetic diagnosis.
Only electronic searches for English language
articles, published between January 1st 1970 and
November 8th 2013, were performed using three
databases; Scopus, Medline via PubMed and Genetics
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Abstracts (Supplementary Tables 1–3). Duplicate arti-
cles were removed. Reference lists and the UniProt
database were checked manually for additional arti-
cles (Supplementary Table 4). Patients described in
multiple articles were included only once. Careful con-
sideration as to whether patients from large, undefined
cohorts could be included was taken. Key search terms
employed included ‘PEO’, ‘CPEO’, ‘ophthalmople-
gia’, ‘ophthalmoparesis’, ‘adult’, and ‘adult-onset’.
RESULTS
Ophthalmoparesis related to mitochondrial disease
retrieved from the electronic searches was described
in 1129 articles. Of these, 160 papers described a total
of 583 PEO patients who met inclusion criteria; har-
bouring mutations of twelve nuclear genes involved
in mitochondrial maintenance and function (Fig. 2).
Many patients described in the literature were not
included in this review, due to symptoms presenting
before 16 years old or the aetiology was not mito-
chondrial. At the time of writing, adult-onset PEO and
mtDNA instability patients with mutations of SPG7
and AFG3L2 were additionally reported and there-
fore there are 597 patients reported in 163 articles
(Fig. 2). Thus, there are fourteen genes associated
with adult-onset PEO and mtDNA instability (Table 1).
All genes are known to localise to the mitochondria
(Fig. 3). These are listed in order of discovery in adult-
onset PEO. The clinical, molecular, and genetic data
for all genes have been summarised (Supplementary
Tables 5–10).
TYMP – thymidine phosphorylase
TYMP encodes thymidine phosphorylase and catal-
yses the conversion of thymidine to thymine and
deoxyuridine to uracil [12]. Depletion of thymi-
dine phosphorylase leads to the accumulation of
thymidine and deoxyuridine, disturbing dNTP sup-
ply and affecting mtDNA synthesis. Mutations cause
mitochondrial neurogastrointestinal encephalopathy
(MNGIE), a multisystem disorder where PEO is a
common symptom. We identified 49 patients who met
the review criteria. It is a recessive disorder with the
majority of patients presenting with mtDNA depletion;
relatively few have been reported to exhibit biochem-
ical evidence of multiple mtDNA deletions [7, 13].
Fig. 2. The study of articles identified using electronic search terms. A study flow diagram summarising the filtering of articles identified by the
electronic searches to include those describing only adult-onset PEO patients and the inclusion of three articles reporting patients with SPG7 or
AFG3L2 mutations, which were not identified systematically.
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Table 1
Summary of genes (n = 14) associated with adult-onset PEO and mtDNA instability
Gene Genotype Effect on mtDNA Number of patients in Number of articles
the literature that meet describing patients
the review criteria 1
POLG Dominant and Multiple deletions 258 64
recessive and depletion
C10ORF2 Dominant and Multiple deletions 143 33
recessive and depletion
TYMP Recessive Multiple deletions 49 32
and depletion
RRM2B Dominant and Multiple deletions 42 6
recessive and depletion
OPA1 Dominant Multiple deletions 42 9
SLC25A4 Dominant Multiple deletions 39 8
SPG7 Dominant and Multiple deletions 12 2
recessive
MGME1 Recessive Multiple deletions 3 1
TK2 Recessive Multiple deletions 3 2
POLG2 Dominant Multiple deletions 3 3
AFG3L2 Dominant Multiple deletions 2 1
DGUOK Recessive Multiple deletions 2 1
DNA2 Dominant Multiple deletions 1 1
MPV17 Recessive Multiple deletions 1 1
1Three patients had digenic mutations i.e. mutations of two different nuclear genes.
Fig. 3. Mendelian disorders of mtDNA maintenance. A cartoon of mitochondrial nucleotide metabolism for mtDNA synthesis, replication and
repair identifying the major genes (italicised in blue) which have been associated with disorders of mtDNA maintenance including adult-onset
PEO and multiple mtDNA deletion syndromes and/or mtDNA depletion and the sub-mitochondrial localisation of the proteins encoded by these
genes.
Patients had depleted thymidine phosphorylase activ-
ity that was characteristically below 5% of controls.
Gastrointestinal dysmotility is the cardinal feature of
MNGIE, although highly variable in severity; common
symptoms included borborygmi, abdominal pain, diar-
rhoea, vomiting, and early satiety. Almost universally
patients were cachectic and reported weight loss in
later life. Gastrointestinal dysmotility was reported in
several patients with other known PEO genes, includ-
ing one patient with recessive RRM2B mutations and
mtDNA depletion [14], but without depleted thymidine
phosphorylase activity. MNGIE phenotype has also
been reported due to mutations in POLG. Thymidine
concentrations are not increased in these patients, sim-
ilar to that seen in RRM2B, and leukoencephalopathy,
which is typical for TYMP mutations, is conspicuously
absent in these cases [15]. Myopathies were reported
in nearly all cases and included muscle weakness and
atrophy. Peripheral and sensory neuropathies (includ-
ing absence of joint reflexes) were also common. Other
features included retinopathy, hearing loss, or both
[13, 16–27]. One peculiar patient with a late-onset
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phenotype had compound mutations of TYMP and
C10ORF2, with no evidence of mtDNA instability
[28], which may explain late manifestation of symp-
toms. Gastrointestinal dysmotility was not reported in
three patients [21, 29]. However, given the distinct, pro-
gressive phenotype, gastrointestinal symptoms were
predicted to present later in life.
Many patients were excluded due to the early-
onset presentation of symptoms, while a small number
presented after the age of 30. Therefore, MNGIE
is an adolescent to early adult-onset disease. TYMP
mutations are rare, but the phenotype is distinct. Nev-
ertheless, there remains a poor correlation between
mutations, age of onset and severity.
SLC25A4 - ADP/ATP translocase 1
SLC25A4 (ANT1) encodes ADP/ATP translocase
1 and is required for the exchange of ADP from
the cytoplasm with ATP generated by the mitochon-
dria [30]. Indolent or mild PEO phenotypes, with or
without ptosis, were described in 39 patients with
SLC25A4 mutations. Neuromuscular symptoms were
largely confined to the extra ocular and facial muscles
[6, 31–33]. Hypoacusia and generalised muscle weak-
ness were also reported in two unrelated families [6].
Diabetes was reported in one patient [34] whilst four
adult PEO patients harbouring SLC25A4 mutations
manifest psychiatric symptoms [32, 34, 35].
While SLC25A4 mutations are indicative of auto-
somal dominant, mild adult-onset PEO phenotypes,
neuropathies and psychiatric symptoms expand the
clinical spectrum. Although a rare cause of adult-onset
PEO, SLC25A4 should be sequenced in suspected
patients with mild or indolent PEO phenotypes.
POLG – DNA polymerase subunit gamma-1
Mutations of POLG, encoding the catalytic subunit
of the only known DNA polymerase of mitochondria,
are amongst the most common pathogenic mutations
found in individuals presenting with PEO and multiple
mtDNA deletions. This review identified 258 adult-
onset PEO patients with mutations in POLG. First
identified as a locus for PEO by Van Goethem et al.
(2001), POLG-related disorders have shown to mani-
fest as a broad phenotypic continuum of overlapping
symptoms in patients with mitochondrial disorders
[36].
POLG related mitochondrial disease is histori-
cally classified according to clinical manifestations
and although most patients may not exhibit all
phenotypic features, clustering of symptoms may aid
clinical recognition and aid diagnosis. The follow-
ing syndromes are recognised: 1) arPEO, usually
characterised by isolated PEO and ptosis; 2) adPEO
is frequently associated with myopathy and other
systemic features; 3) ataxia neuropathy spectrum
(ANS) combines the previous syndromes of mito-
chondrial recessive ataxia syndrome (MIRAS) and
sensory ataxia neuropathy, dysarthria and ophthalmo-
plegia (SANDO), in which cardinal features of ataxia
and neuropathy manifest in over 90% of individu-
als, with other clinical features presenting to a lesser
degree including seizures (≈65%) and PEO (≈50%).
Myopathy is rare. Myoclonic epilepsy myopathy sen-
sory ataxia (MEMSA) now envelops the syndrome
of spinocerebellar ataxia with epilepsy (SCAE) and
includes epilepsy, myopathy, and ataxia without PEO
[37]. Two other syndromic disorders related to POLG
are recognised to present in childhood and include
Alpers-Huttenlocher syndrome (AHS) and Childhood
myocerebrohepatopathy spectrum (MCHS) disorder,
but are not within the remit of this review. Additional,
non-syndromic clinical features have been described.
Ataxia was a frequent clinical feature in adult-onset
PEO patients with mutations in POLG; having been
reported in over 40% of cases; a figure not dissimi-
lar to the incidence reported in a previous multicenter
case series [36]. Ataxia was specifically related to
the presence of an often debilitating peripheral sen-
sory neuronopathy [38] in over 20% of adult-onset
PEO patients with mutations in POLG (Supplemen-
tary Table 7). We would suggest, however, that these
figures may represent an under estimation as only more
recent publications have discerned between peripheral
and central components of ataxia, that is, ataxia due
either to cerebellar dysfunction or pathology of the
dorsal root ganglion. Premature ovarian failure (POF)
was also observed in a small number of female patients
[15, 39, 40]. Other symptoms included dysphagia,
dysarthria and diabetes mellitus. Psychiatric symp-
toms were particularly prevalent in patients harboring
mutations of POLG. Parkinsonism was described in
38 patients [35, 40–57]. Dementia was reported more
frequently than would be expected by chance [36, 56,
58–61] as was depression [15, 35, 40, 41, 45, 50, 54,
55, 62–66]. POLG-related encephalopathy was a hall-
mark feature in patients comprising of, but not limited
to, seizure disorders (status epilepticus, myoclonus,
grand mal seizures) and neurological manifestations,
comparable to mitochondrial encephalopathy, lactic
acidosis and stroke-like episodes syndrome (MELAS)
[36, 39, 46–49, 54, 58, 60–66]; with the conspicuous
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absence of temporal lobe involvement [67, 68].
MNGIE-like phenotypes with preserved thymidine
phosphorylase levels have also been reported in POLG
patients [15].
This review identified 85 different mutations in
POLG presenting as adult-onset PEO. These were
mainly missense mutations demonstrating dominant
inheritance or occurring sporadically (Supplementary
Table 8). There was great disparity in the frequency
of mutations; the most commonly occurring were
the p.(Ala467Thr), p.(Trp748Ser), and p.(Thr251Ile)
p.(Pro587Leu) mutations (Supplementary Table 8).
The most prevalent pathogenic mutation in POLG
reported in the Caucasian population is a c.1399G>A
leading to p.(Ala467Thr) missense mutation in the
linker domain of the protein [69]. Although, the
homozygous p.(Ala467Thr) POLG mutation was orig-
inally reputed to cause discrete phenotypes, this has
subsequently been revised to a continuum of clini-
cal symptoms and hence demonstrates the underlying
challenge of diagnosing POLG-related PEO.
C10ORF2 – twinkle
C10ORF2 encodes the mitochondrial protein twin-
kle, a DNA helicase that catalyses the ATP-dependent
unwinding of mtDNA in the 5’ to 3’ direction, essential
for mtDNA replication, and co-localises with mtDNA
in mitochondrial nucleoids [4, 70]. Both adPEO and
arPEO was reported in 143 patients with C10ORF2
mutations, presenting a broad phenotypic spectrum.
Proximal and facial muscle weakness, gait disturbance,
exercise intolerance and fatigue were particularly
prevalent. Other clinical manifestations included dia-
betes mellitus, visual loss or impairment, diplopia,
hearing loss, ataxia, and seizures [71–73].
Parkinsonism was described in seven patients,
including one with compound mutations of C10ORF2
and TYMP [27]. Psychiatric symptoms were partic-
ularly prevalent and included depression, avoidant
personalities, migraines, dementia, and Alzheimer’s
disease [4, 71, 72, 74]. Scattered white matter lesions
were also found in a single case, but with no apparent
psychiatric or stroke-like symptoms [75].
Cardiac involvement was also reported, including
one patient with right bundle branch block [76], and
left ventricular hypertrophy in a sizeable cohort of
patients [9]; whilst coronary artery involvement was
peculiar to a Chinese family with familial heart dis-
ease [77]. Congestive cardiac failure was described in
a mixed consanguineous Saudi Arabian family with
a dominant mutation, who also presented with severe
hepatopathy and acute encephalopathy [78]. Multiple
mtDNA deletions were detected in all patients where
such analyses were performed, but were not always
prominent. Depletion was detected in one patient, in
addition to multiple mtDNA deletions [79]. Reces-
sively inherited mutations generally resulted in a severe
early-onset phenotype, but again there was no clear
genotype-phenotype correlation. Given the broad phe-
notypic spectrum, sequencing of C10ORF2 should be
considered for all suspected adult-onset PEO patients,
particularly those with psychiatric symptoms.
OPA1 – dynamin-like 120 kDa protein
OPA1 encodes the mitochondrial dynamin-like 120
kDa protein localises to the mitochondrial inner mem-
brane and is important for regulation of mitochondrial
fusion and morphology [80, 81]. The review criteria
were amended for patients with OPA1 mutations to
allow patients with onset of symptoms before 16 years
old to be included; the OPA1 phenotype typically pre-
sented from birth or early in life. The 42 PEO patients
with heterozygous OPA1 mutations presented with
optic atrophy and visual loss, often leading to blind-
ness and sometimes colour vision abnormalities in the
first decade of life. PEO and mitochondrial symptoms
occurred in adult life, with many patients also harbour-
ing multiple mtDNA deletions. Sensorineural hearing
loss was the most prominent of these symptoms, and
was almost universal in all patients. Ataxia, axonal
neuropathy, ptosis, muscle weakness and exercise
intolerance were also frequently described. Migraines,
diabetes, dementia and epilepsy were described in
some patients, expanding the phenotypic spectrum
[82]. Hypogonadism and macrocytic anaemia were
reported in one patient who was initially diagnosed
with a heterozygous POLG2 mutation [83].
OPA1 mutations had been previously reported as
an important cause of dominant optic atrophy and
visual loss, with other symptoms increasingly recog-
nised after the first described cases [84]. Optic atrophy
in childhood followed by ophthalmoplegia in adult life
had also been reported earlier in the literature, but
initially had been genetically undetermined [85, 86].
The phenotype is similar to Leber Hereditary Optic
Neuropathy (LHON), where three mtDNA point muta-
tions (m.3460G>A, m.11778G>A, and m.14484T>C)
accounted for over 90% of patients of patients in the
north east of England, with a predicted overall popu-
lation prevalence of one in 25,000 [87].
Phenotypically, OPA1 mutations are distinct and
should be considered in all patients presenting with
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optic atrophy in childhood, irrespective if mitochon-
drial disease is suspected.
POLG2 – DNA polymerase subunit gamma-2
POLG2 encodes the mitochondrial DNA poly-
merase accessory subunit and binds to single-stranded
DNA, which is necessary for mtDNA replication and
embryogenesis [88].
Three adult-onset PEO patients, harbouring het-
erozygous POLG2 mutations, all presented with PEO,
ptosis and muscle weakness to varying degrees. How-
ever, a broad range of additional symptoms was
described. One patient had marked ataxia and cere-
bellar features and was unable to tandem gait [89].
Another patient presented with gastrointestinal symp-
toms and a dystrophy-like distribution of muscle
weakness [90]. The third patient presented with a
cardiac conduction defect and had impaired glucose
tolerance [91]. Although presenting with a broad spec-
trum of symptoms, PEO and ptosis with a proximal
myopathy was present in all three patients. Classifica-
tion of POLG2 mutations remains difficult due to the
small number of patients reported, although a number
of early-onset patients with recessive mutations had
also been described [90]. POLG2 screening should be
considered in all suspected adult-onset PEO patients,
but is a rare cause of mitochondrial disease.
RRM2B – ribonucleoside-diphosphate reductase
subunit M2 B
RRM2B encodes ribonucleoside-diphosphate reduc-
tase subunit M2 B (p53R2), is important for DNA
repair and is inactivated in many cancers [92]. It has a
similar role in the maintenance and repair of mtDNA,
but is also essential for dNTP supply for mtDNA repli-
cation [93].
Similar to POLG and C10ORF2, RRM2B muta-
tions resulted in a broad phenotypic spectrum in 42
adult-onset PEO patients. This included mild PEO,
with or without ptosis, muscle weakness and exer-
cise intolerance [5]. Hearing loss was also frequently
reported, while muscle atrophy and fatigue was also
prevalent [10, 94, 95]. Anxiety and depression was
reported in one patient [10]. The MNGIE-like phe-
notype was described in one patient with mtDNA
depletion [14], and was comparable to early-onset
patients with RRM2B mutations [93].
RRM2B mutations, representing the third largest
number of adult-onset PEO patients, present broad
symptoms in patients, but are unlikely to be the cause
of multisystem disorders. Overall, this suggests that
RRM2B should be sequenced in all suspected patients
with adult-onset PEO; particularly in those manifesting
additional systemic features including bulbar, hearing
loss and gastrointestinal dysmotility.
TK2 – thymidine kinase 2
TK2 encodes thymidine kinase 2, which phosphory-
lates thymidine, deoxycytidine, and deoxyuridine and
is essential for dNTP generation for mtDNA replica-
tion. Three patients have been reported to date with
recessive TK2 mutations with multiple mtDNA dele-
tions and presented late in life. Two sisters presented
with ptosis in the fourth and fifth decades of life, which
progressed to ophthalmoparesis and proximal muscle
weakness [8]. Scapular winging, dysphagia, and res-
piratory deficiency were common to both. One sibling
also had evidence of skin sarcoidosis and mild muscle
atrophy. The third unrelated patient had sensorineu-
ral hearing loss with mild ptosis, subtle PEO, facial
weakness, proximal muscle wasting, including scapu-
lar winging and weakness of sternocleidomastoids, and
neck flexion [96].
All three patients had late onset and slowly progres-
sive myopathies including respiratory insufficiency, in
addition to central nervous system involvement [8].
Depletion disorders related to TK2 mutations are often
more severe and lead to premature death [97]. Muta-
tions of TK2 leading to PEO are apparently rare, but
should be considered where generalised muscle weak-
ness and wasting and respiratory failure are prominent.
DGUOK – deoxyguanosine kinase
DGUOK encodes deoxyguanosine kinase and is
required for the first step of salvage of deoxyri-
bonucleotides in the mitochondria, essential to
mitochondrial genome maintenance [98]. Disease
onset in two patients with recessiveDGUOKmutations
was very late in life [11]. The first patient presented
with isolated PEO and ptosis at age 58 years. Marked
exercise intolerance was also reported in a sibling. The
second patient presented with bilateral ptosis and PEO
in their sixth decade of life and complained of upper
and lower limb girdle weakness with leg cramps in
later life. Occasional dysphagia for liquids was also
reported. Family history was negative for muscle dis-
orders. Both patients harboured recessive DGUOK
mutations that had been previously reported in early-
onset mitochondrial disease patients with mtDNA
depletion [99]. DGUOK mutations remain associated
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in early-onset mitochondrial disease causing hepato-
cerebral mitochondrial depletion [100] and a very rare
cause of late-onset PEO.
MPV17 – protein MPV17
The role of protein MPV17 in mitochondrial
maintenance, encoded by MPV17, remains poorly
understood, but it is known to localise to the mito-
chondrial inner membrane [101]. A single patient who
presented with distal limb weakness and numbness
at 34 years old [102] was initially diagnosed with
Charcot-Marie tooth disease after nerve conduction
studies and EMG results. This progressed to proximal
limb weakness, exercise intolerance, diabetes mel-
litus, ptosis, ophthalmoparesis, hearing loss, severe
constipation due to gastrointestinal dysmotility, and
depression in the fifth decade of life. At 65 years
the patient developed parkinsonism characterised by
bradykinesia, bilateral resting tremor, and mild rigid-
ity. The patient also had a fatty liver and interestingly
a sibling died of unexplained liver failure at 39 years
old.
MPV17 mutations had previously been reported
in early-onset mitochondrial disease with mtDNA
depletion [103] with ophthalmoplegia, axonal sensory-
motor neuropathy and preceding liver dysfunction
observed, whereas parkinsonism and gastrointestinal
symptoms were additional features. Therefore,MPV17
mutations are an apparently rare cause of adult-onset
mitochondrial disease.
MGME1 – mitochondrial genome maintenance
exonuclease 1
MGME1 (C20ORF72) encodes mitochondrial
genome maintenance exonuclease 1. MGME1 is
essential for mitochondrial genome maintenance by
cleaving single-stranded DNA and processing DNA
flap substrates, while also necessary for maintaining
7S DNA levels [104, 105].
Three patients have presented with mild bilateral
ptosis followed by progressive ophthalmoplegia late
in life [104]. Proximal muscle weakness, generalised
muscle wasting, respiratory deficiency and dyspnea
were characteristic in all patients. Chronic renal failure,
cardiac arrhythmias, depressive episodes, and memory
lapses were reported in one patient, while two affected
brothers had mild kyphosis. Although the patients pre-
sented with a similar phenotype, there were no other
cases in the literature to allow comparison.
DNA2 – DNA replication ATP-dependent
helicase/nuclease DNA2
Studies of DNA2 are limited, but suggest that
hDNA2 co-localises with a subfraction of mitochon-
drial nucleoids containing mtDNA but is also present
in the nucleus [106]. Levels of hDNA2 accumulated
within the nucleoids with disease-associated muta-
tions of twinkle, whereas depletion led to a decrease
of mtDNA replication intermediates and inefficient
repair of damaged mtDNA, suggesting a role in nuclear
and mtDNA repair maintenance. One patient, harbour-
ing a heterozygous mutation with multiple mtDNA
deletions, had lower limb weakness, ophthalmoplegia,
diplopia and myalgia at 55 years old, with onset at
35 years old [107]. This progressive myopathy was
similarly observed in early-onset patients with DNA2
mutations. With only one adult patient reported, DNA2
mutations are therefore an extremely rare cause of
adult-onset mitochondrial disease.
SPG7 – paraplegin
SPG7 encodes paraplegin, which localises to the
mitochondrial inner membrane [108]. Twelve patients
with SPG7 mutations and PEO with multiple mtDNA
deletions who met the review criteria were reported
using whole exome sequencing [109, 110]. Nine
patients presented with the classic spastic paraplegia
phenotype observed in previously reported patients
[108], whereby PEO and multiple mtDNA deletions
were previously unreported. Six patients had cere-
bellar atrophy evident on MRI imaging. Compound
SPG7mutations were identified in eight patients, while
four had heterozygous mutations, including one patient
with isolated PEO. However, the typical presentation
was onset of either PEO/ptosis and spastic ataxia, or a
progressive ataxia disorder. Strikingly, eleven patients
were identified from a cohort of 68 patients with undi-
agnosed PEO and multiple mtDNA deletions [109],
indicating that SPG7 mutations are a common cause of
adult-onset PEO and should be sequenced in patients
with undetermined PEO.
AFG3L2 - AFG3-like protein 2
AFG3L2 encodes AFG3-like protein 2, which forms
a homo-oligomer, an m-AAA protease, with para-
plegin in the mitochondrial inner membrane [111,
112]. Whole exome sequencing identified two patients
with dominant AFG3L2 mutations [113]. Both pre-
sented with late-onset, slowly progressive ptosis and
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Table 2
Summary of body systems affected by adult-onset PEO gene mutations
Gene Muscle Central Nervous Psychiatric Cardiovascular Endocrine Digestive Respiratory Reproductive Urinary
System (CNS)
POLG ++ ++ + + + + − + −
C10ORF2 ++ + ++ + + + − + −
TYMP ++ ++ + − − ++ − − −
RRM2B ++ ++ + + − + + − +
OPA1 ++ ++ + − − + − − −
SLC25A4 ++ + + − + − − − −
SPG7 ++ ++ + − − − − − +
MGME1 ++ − + + − − ++ − +
TK2 ++ + − − − − + − −
POLG2 ++ ++ − − − + + − −
AFG3L2 ++ ++ − − − − − − −
DGUOK ++ − − − − − − − −
DNA2 ++ − − − − − − − −
MPV17 ++ ++ ++ − ++ ++ − − −
++denotes body systems frequently affected by mutations. +denotes body systems rarely affected by mutations. –denotes mutations that are
not affected by mutations.
ophthalmoparesis with slurred speech and lower limb
muscle weakness. The first patient had a family his-
tory of ataxia and had an indolent gait and limb ataxia
seen in her teens, progressing to a broad-based ataxic
gait upon clinical examination, with dysmetria and
dysarthria. The second patient had slowly progressive
ataxia and lower limb spasticity with marked cerebellar
atrophy, but without prior family history.
AFG3L2 mutations had typically been associated
with autosomal dominant spinocerebellar ataxia 28
(SCA28) [112]. Thus far, with only two patients cur-
rently reported, AFG3L2 mutations are therefore a rare
cause of PEO with multiple mtDNA deletions. Never-
theless, AFG3L2 sequencing should be considered for
patients presenting with PEO and ataxia, spasticity, or
both.
DISCUSSION
We have identified fourteen nuclear genes (twelve
systematically) whereby mutations lead to adult-onset
PEO with mtDNA instability. A total of 583 patients
with a confirmed genetic diagnosis were described
in 160 articles, with large variation in the quality
of patient reporting. A further fourteen patients with
either SPG7 or AFG3L2 mutations were also recently
reported in three papers, giving a total of 597 patients in
163 articles who met the review criteria. Those describ-
ing patients in the greatest detail were considered of a
high quality. Age of onset was not reported for many
patients, particularly those detailed in large patient
cohorts. Also, mtDNA instability was not determined
for all patients, perhaps due to a lack of skeletal muscle
tissue available. Furthermore, the diverse symptoms
and phenotypes presented by the patients meant that
a meta-analysis and statistical comparisons was not
possible.
This systematic review has confirmed the broad
spectrum of symptoms affecting multiple body systems
in adult-onset PEO patients with mtDNA instability
with adPEO the predominant manner of inheri-
tance (Table 2). While genotype-phenotype correlates
remain challenging clear clinical patterns are emerg-
ing. POLG and C10ORF2 mutations present with the
broadest phenotypes, and represent over 65% of all
patients in the literature (Table 1). Yet, PEO, ptosis
and proximal muscle weakness are perceived as promi-
nent clinical features in adult patients with mutations
in both POLG and C10ORF2. It is not uncommon for
the same heterozygous POLG or C10ORF2 mutations
to cause different clinical manifestations, reflecting
the vast complexity of PEO. SLC25A4 and C10ORF2
mutations generally result in indolent PEO pheno-
types, with or without mild proximal muscle weakness,
whilst POLG2 mutations often present with a proximal
myopathy that is universally present in all patients.
Parkinsonism in late onset PEO cases would sug-
gest screening for POLG mutations. Sensory ataxia
is also prominent and suggestive of POLG mutations.
Additional systemic features including bulbar, hearing
loss and gastrointestinal dysmotility should preferen-
tially direct testing towards RRM2B genetic analysis.
Screening for TK2 mutations should be considered
in cases of suspected mtDNA maintenance disorders
and late onset-myopathy in which respiratory failure
is prominent. Proximal muscle weakness, generalised
muscle wasting, emaciation and respiratory failure are
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also prominent features in patients withMGME1muta-
tions. However, these patients classically present at an
earlier age than those harbouring TK2 mutations.
Mutations in three PEO genes exhibit discreet
characteristic phenotypes including TYMP, OPA1 and
SPG7. Recessive TYMP mutations cause the fatal mul-
tisystem disorder MNGIE, characterised by marked
gastrointestinal dysmotility with age of presentation
often ranging from the first to third decades of life [7].
Autosomal dominant or sporadic OPA1 mutations fre-
quently present with optic atrophy and varying degrees
of visual loss in early-life, followed by ophthalmo-
paresis, hearing loss and mitochondrial myopathy in
adult-life [84]. And most recently, spastic ataxia is
recognised as a cardinal clinical finding in adult-PEO
patients harbouring SPG7 mutations [109, 110].
Nevertheless, although clinical patterns are emerg-
ing, clinical manifestations still remain varied and this
should not deter screening of all maintenance disorder
genes in suspected mitochondrial disease patients with
PEO, if initial genetic testing proves negative.
CONCLUSION
In many cases of PEO, the underlying genetic defect
remains either due to a single large scale rearrangement
of mtDNA or point mutation. However, a considerable
group of PEO patients is increasingly recognised, who
harbour multiple mtDNA deletions in skeletal muscle.
PEO remains the most common presenting neu-
rological hallmark seen in adults with mtDNA
maintenance disorders, with the clinical phenotype
quite often not restricted to extraocular muscles.
Despite marked clinical overlap between mitochon-
drial maintenance genes, key clinical features are
emerging that will help direct prioritization of genetic
testing and screening of variants identified by whole
exome and whole genome studies and may, eventu-
ally, preclude the need for a muscle biopsy. Careful
clinical evaluation documenting personal and family
history, and the use of supportive clinical investiga-
tions to document the extent of phenotype are key to
building clinical evidence in support of genetic diag-
noses that will provide both patients and physicians
with guidance about diagnosis, future prognosis and
evaluation of potential therapeutic strategies.
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